RemeGen Co., Ltd.
RemeGen Co., Ltd.
Explore linked clinical trials.36 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma | renal pelvis/ureter urothelial carcinoma | Recruiting | Phase 3 | 2026-09-28 | NCT07498907 | |
| A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors | Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT07537881 | |
| A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-23 | NCT04400695 | |
| Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | Not yet recruiting | Phase 3 | 2026-09-22 | NCT07829549 | |
| A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric carcinoma, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07315750 | |
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT05745740 | |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, digestive system disorder, digestive system neoplasm, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, skin disorder, stomach disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-07-22 | NCT06157892 | |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 3 | 2026-07-22 | NCT05911295 | |
| RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-07-14 | NCT07416474 | |
| A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-05-22 | NCT07462143 | |
| Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease | CTD-ILD | Not yet recruiting | Phase 3 | 2026-04-09 | NCT07495033 | |
| A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | Myasthenia Gravis, Ocular, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-04-09 | NCT07249632 | |
| A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer | gastric adenocarcinoma | Not yet recruiting | Phase 2 | 2026-04-02 | NCT07507526 | |
| A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-03-05 | NCT06883630 | |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2025-12-16 | NCT05799287 | |
| A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors | Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-11-26 | NCT07105215 | |
| DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-10-01 | NCT06178159 | |
| A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 2 / Phase 3 | 2025-09-29 | NCT05980481 | |
| RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Not yet recruiting | Phase 2 | 2025-08-03 | NCT07100184 | |
| A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2025-07-16 | NCT06962865 | |
| A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric carcinoma, gastric neoplasm, neoplasm, stomach disorder | Not yet recruiting | Phase 3 | 2025-04-25 | NCT06944496 | |
| Neoadjuvant Therapy in Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Not applicable | 2025-04-01 | NCT06558682 | |
| Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-02-17 | NCT06642545 | |
| A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2025-01-27 | NCT05205850 | |
| A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2025-01-23 | NCT06016062 |